FDA Accepts Brepocitinib NDA; Priority Review Assigned for Dermatomyositis

Priovant Therapeutics reported that the FDA has accepted its New Drug Application for brepocitinib for the treatment of dermatomyositis and granted the application Priority Review. In the same announcement, the company said the agency assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026. Priovant also stated that it expects a U.S. launch at the end of September 2026, describing that timing as the company’s expectation during the review process.

Support for the filing was attributed to results from the Phase 3 VALOR trial as described by the company. Priovant characterized VALOR as a global study enrolling 241 subjects with dermatomyositis across about 90 sites, with randomization in a 1:1:1 ratio to brepocitinib 30 mg, brepocitinib 15 mg, or placebo. The release situates the primary comparison and reported readouts within a one-year double-blind treatment period, with assessments described through Week 52. Priovant cited the VALOR dataset as the clinical evidence base supporting the NDA submission.

For efficacy, Priovant reported statistically significant improvement for brepocitinib 30 mg versus placebo on the primary endpoint, the myositis Total Improvement Score (TIS), at Week 52. The company also stated that benefit versus placebo was observed as early as Week 4 and sustained at each visit thereafter through the end of the double-blind period. In the same release, Priovant said that more than two thirds of patients receiving 30 mg achieved a TIS of at least 40, and that all nine key secondary endpoints were met. The announcement framed these efficacy findings as supportive of the regulatory filing.

The press release also summarized safety observations from VALOR while distinguishing them from broader program experience. Priovant stated that serious infections were increased in the brepocitinib 30 mg arm compared with placebo, and it added that these events resolved with medical management, with treatment completed in most cases. By contrast, the company reported that new or recurrent malignancy, cardiovascular events, and thromboembolic events occurred more frequently in the placebo arm than in the 30 mg arm. Beyond VALOR, Priovant said the brepocitinib safety database across studies includes more than 2,000 patients and subjects and “suggests a safety profile similar to approved JAK and TYK2 inhibitors.” These statements were presented as part of the company’s safety summary.

In reiterating the regulatory timeline, Priovant reported FDA acceptance of its New Drug Application (NDA) for brepocitinib in dermatomyositis, a Priority Review designation, and a PDUFA target action date in the third quarter of calendar year 2026. The release also includes a general description of Priority Review as applying to medicines that, if approved, provide significant improvements in safety or effectiveness for a serious condition, and it notes unmet medical need in dermatomyositis in that context. The press release does not detail formulary or coverage planning steps or special-population prescribing considerations beyond the specific safety observations it reports. Overall, the update reads as a company-presented recap of regulatory timing alongside the Phase 3 findings it cites in support of the submission.

Key Takeaways:

• Priovant reported FDA acceptance of its NDA for brepocitinib in dermatomyositis, a Priority Review designation, and a PDUFA target action date in Q3 2026, alongside an expected U.S. launch timing stated by the company.
• The company described VALOR as a global Phase 3 trial and reported that the 30 mg dose met the primary TIS endpoint and all nine key secondary endpoints, with an early and sustained treatment effect as presented in the release.
• Priovant highlighted increased serious infections in the 30 mg arm versus placebo in VALOR, noted certain event categories occurred more frequently in placebo, and pointed to a broader >2,000-patient safety database described as similar to approved JAK and TYK2 inhibitors.